BioSpace News Archive

Elixiron Immunotherapeutics, a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its colony stimulating factor‑1 receptor (CSF‑1R) inhibitor, EI‑1071 for the treatment of idiopathic pulmonary fibrosis (IPF).

As per Vision research Reports, the global dystrophic epidermolysis bullosa treatment market size is predicted to hit around US$ 715 million by 2030 from valued US$ 415 Mn in 2020, expanding growth at a CAGR of 5.1% from 2022 to 2030.

AMC Health, the leading Remote Patient Monitoring (RPM) and Virtual Care services provider, is pleased to announce a strategic partnership with Magnolia Regional Health Center (MRHC).

PharmaJet®, a biotech company that, with their innovative needle-free technology, has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that its partner, Scancell, will include needle-free delivery of their Phase 2 clinical study for treatment of patients with advanced melanoma.

Element Science, an innovative health technology company pioneering a next-generation digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, today announced the first patient save from a successful defibrillation early in the enrollment of the Investigational Device Exception (IDE) Study of its Jewel Patch Wearable Cardioverter Defibrillator (P-WCD).

The latest market analysis report published by Reports and Data, titled ‘Global Genital Herpes Treatment Market – Forecast to 2030,’ thoroughly examines the Genital Herpes Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Dyslipidemia Treatment Market – Forecast to 2030,’ thoroughly examines the Dyslipidemia Treatment industry to provide essential data & information for the targeted readers. The report consists of quantitative and qualitative research on the market performed by our market experts

GUELPH, ON – eQcell Inc., a Canadian clinical-stage company, and Tillsonburg, Ontario-based private equity fund Ag Capital Canada (ACC) are pleased to announce the completion of a C$1.1 million capital investment.

GlobeStar Therapeutics Corporation, headquartered in Richland, Washington, is a clinical stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced details from preclinical poster presentations at the Alzheimer’s Association International Conference (AAIC) 2022.